Table 2

Metabolites of atomoxetine identified in urine from CYP2D6 extensive and poor metabolizer subjects following oral administration of14C-atomoxetine2-a

CompoundPoor Metabolizer SubjectsExtensive Metabolizer Subjects
Subject 1Subject 4Subject 7Subject 2Subject 3Subject 5Subject 6
4-Hydroxy-N-desmethylatomoxetine + 2-b + N.D. + N.D.N.D.N.D.
4-Hydroxyatomoxetine + + + + + + +
2-Hydroxymethylatomoxetine + + + + + + +
Hydroxyatomoxetine (1)2-c N.D. + + + + N.D.N.D.
Hydroxyatomoxetine (2)2-c + N.D.N.D. + N.D.N.D.N.D.
N-Desmethylatomoxetine + + + N.D.N.D.N.D.N.D.
4-Hydroxy-N-desmethylatomoxetine-O-glucuronide + + + + + + +
4-Hydroxyatomoxetine-O-glucuronide + + + + + + +
2-Hydroxymethylatomoxetine-O-glucuronide + + + + + + +
Dihydroxyatomoxetine-O-glucuronide (1)2-c + + + + + + +
Dihydroxyatomoxetine-O-glucuronide (2)2-c N.D. + + N.D.N.D.N.D.N.D.
4-Hydroxy-2-carboxyatomoxetine-O-glucuronide + + + + N.D. + +
Hydroxy carboxyatomoxetine-O-glucuronide2-a + + + + + + +
Atomoxetine + + + + + + +
  • N.D., not detected.

  • 2-a  Multiple 20-mg doses of atomoxetine were administered twice daily over 5 days followed by a single radiolabeled atomoxetine 20-mg dose (actual dose 19.66 mg; 92.4 μCi) on the morning of the 6th day.

  • 2-b  A plus sign indicates that parent drug or the metabolite was observed in urine.

  • 2-c  Specific hydroxylation sites for these metabolites have not been defined.